SNSE | tickerfilter.com

Fundamental analysis

37%

Profitability 35%

Dept financing 22%

Liquidity 50%

Performance 40%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-3.28%

1 Month

234.47%

3 Months

244.22%

6 Months

247.06%

1 Year

6,824.88%

2 Year

2,969.40%

Key data

Stock price

$29.50

P/E Ratio

0.00

DAY RANGE

$28.26 - $30.55

EPS

-$4.48

52 WEEK RANGE

$0.25 - $36.76

52 WEEK CHANGE

$6,839.54

MARKET CAP

11.919 M

YIELD

N/A

SHARES OUTSTANDING

1.261 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-08-2025

BETA

1.00

PUBLIC FLOAT

AVERAGE 10 VOLUME

$135,753

AVERAGE 30 VOLUME

$774,156

Company detail

CEO: John K. Celebi
Region: US
Website: senseibio.com
Employees: 40
IPO year: 2021

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Sensei Biotherapeutics, Inc. engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer.

SNSE - Sensei Biotherapeutics Inc